A comparative thermal, structural and luminescence studies of 2-chloro-5-nitrobenzoate salts

Croitor Lilia; Petric M.; Vlase Gabriela; Vlase Titus; Bourosh Pavlina; Siminel Anatolii; Crişan Manuela E.

Articolul precedent

Articolul urmator

678

Ultima descărcare din IBN:
2023-04-28 11:12

SM ISO690:2012

CROITOR, Lilia, PETRIC, M., VLASE, Gabriela, VLASE, Titus, BOUROSH, Pavlina, SIMINEL, Anatolii, CRIŞAN, Manuela E.. A comparative thermal, structural and luminescence studies of 2-chloro-5-nitrobenzoate salts. In: Book of Abstracts: of the 28th Symposium on Thermal Analysis and Calorimetry – Eugen Segal – of the Commission for Thermal Analysis and Calorimetry of the Romanian Academy (CATCAR28), Ed. 28, 9-10 mai 2019, Chişinău. România, Arad: Gutenberg Univers Arad Publishing House, 2019, p. 57. ISBN 978-606-675-208-4.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Book of Abstracts 2019

Simpozionul "28th Symposium on Thermal Analysis and Calorimetry – Eugen Segal – of the Commission for Thermal Analysis and Calorimetry of the Romanian Academy (CATCAR28) "
28, Chişinău, Moldova, 9-10 mai 2019

A comparative thermal, structural and luminescence studies of 2-chloro-5-nitrobenzoate salts

Pag. 57-57

Croitor Lilia¹², Petric M.², Vlase Gabriela³, Vlase Titus³, Bourosh Pavlina¹, Siminel Anatolii¹, Crişan Manuela E.²

¹ Institute of Applied Physics,
² Institute of Chemistry Timisoara of the Romanian Academy,
³ West University of Timisoara

Disponibil în IBN: 19 mai 2020

Descarcă PDF

Rezumat

The active pharmaceutical ingredient 2-chloro-5-nitrobenzoic acid (2Cl5NB) is an antiviral agent for immunodeficiency diseases, including the human immunodeficiency virus (HIV) infection [1]. Taking into account today pharmaceutical industrial challenges, the goal of this study was to obtain and characterize new 2Cl5NB molecular salts based on pharmaceutical active monoethanolamine (MEA) anion. MEA is a naturally occurring component, used as base chemical in the production of pharmaceuticals and recently as therapeutic agent in the treatment of age-associated human diseases [2]. Herein, we present a comparative study of crystal structures, thermal stability, decomposition, kinetics and luminescent properties of two different molecular salts monoethanolammonium 2-chloro-5-nitrobenzoate (1) and N-(1,1- dimethyl-3-oxobutyl)monoethanolammonium 2-chloro-5-nitrobenzoate (2), obtained by different reaction mechanisms of 2Cl5NB with MEA, in diethylether, respectively acetone. The crystal structure determination reveals that compound 1 crystallizes in triclinic P-1 (№2) space group [3], while 2 in monoclinic P21/c (№14) space group: a=9.0876(6), b=26.7814(14), c=7.1888(5) Å, β=93.342(6)°, V= 1746.62 Å3 and both compounds are dominated by charge-assisted O–H···O– and N+ –H···O– hydrogen bonds. Thermal analysis exhibits similar melting points at ~ 120°C and an improved thermal stability for compound 2 compared to 1. In addition, a kinetic study under nonisothermal conditions was performed, using three different methods KissingerAkahira-Sunose (KAS), Friedman (FR), and nonparametric kinetics method (NPK).figureFigure 1. View of asymmetric units and thermoanalytical curves of 1 (a) and 2 (b) Figure 2. Thermal analysis for compounds 1 (red) and 2 (blue).

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-103934</cfResPublId>
<cfResPublDate>2019</cfResPublDate>
<cfStartPage>57</cfStartPage>
<cfISBN>978-606-675-208-4</cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/103934</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>A comparative thermal, structural and luminescence studies of 2-chloro-5-nitrobenzoate salts</cfTitle>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>The active pharmaceutical ingredient 2-chloro-5-nitrobenzoic acid (2Cl5NB) is an antiviral agent for immunodeficiency diseases, including the human immunodeficiency virus (HIV) infection [1]. Taking into account today pharmaceutical industrial challenges, the goal of this study was to obtain and characterize new 2Cl5NB molecular salts based on pharmaceutical active monoethanolamine (MEA) anion. MEA is a naturally occurring component, used as base chemical in the production of pharmaceuticals and recently as therapeutic agent in the treatment of age-associated human diseases [2]. Herein, we present a comparative study of crystal structures, thermal stability, decomposition, kinetics and luminescent properties of two different molecular salts monoethanolammonium 2-chloro-5-nitrobenzoate (1) and N-(1,1- dimethyl-3-oxobutyl)monoethanolammonium 2-chloro-5-nitrobenzoate (2), obtained by different reaction mechanisms of 2Cl5NB with MEA, in diethylether, respectively acetone. The crystal structure determination reveals that compound 1 crystallizes in triclinic P-1 (№2) space group [3], while 2 in monoclinic P21/c (№14) space group: a=9.0876(6), b=26.7814(14), c=7.1888(5) &Aring;, &beta;=93.342(6)&deg;, V= 1746.62 &Aring;3 and both compounds are dominated by charge-assisted O&ndash;H&middot;&middot;&middot;O&ndash; and N+ &ndash;H&middot;&middot;&middot;O&ndash; hydrogen bonds. Thermal analysis exhibits similar melting points at ~ 120&deg;C and an improved thermal stability for compound 2 compared to 1. In addition, a kinetic study under nonisothermal conditions was performed, using three different methods KissingerAkahira-Sunose (KAS), Friedman (FR), and nonparametric kinetics method (NPK).</p><p>figure</p><p>Figure 1. View of asymmetric units and thermoanalytical curves of 1 (a) and 2 (b) Figure 2. Thermal analysis for compounds 1 (red) and 2 (blue).</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-13203</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-61113</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63334</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63336</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-197</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-1069</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-63332</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-13203</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-13203-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Croitor</cfFamilyNames>
<cfFirstNames>Lilia</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-61113</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-61113-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Petric</cfFamilyNames>
<cfFirstNames>M.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63334</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63334-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Vlase</cfFamilyNames>
<cfFirstNames>Gabriela</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63336</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63336-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Vlase</cfFamilyNames>
<cfFirstNames>Titus</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-197</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-197-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Bourosh</cfFamilyNames>
<cfFirstNames>Pavlina</cfFirstNames>
<cfFamilyNames>Боурош</cfFamilyNames>
<cfFirstNames>Павлина</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-1069</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-1069-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Siminel</cfFamilyNames>
<cfFirstNames>Anatolii</cfFirstNames>
<cfFamilyNames>Симинел</cfFamilyNames>
<cfFirstNames>Анатолий</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-63332</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-63332-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Crişan</cfFamilyNames>
<cfFirstNames>Manuela E.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>